Abstract 5430: Left Atrial Appendage Occlusion versus Oral Anticoagulation for Anticoagulation Eligible Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis
Abstract
Background: Left atrial appendage occlusion (LAAO) is an established non-pharmacological alternative to oral anticoagulants (OACs) in atrial fibrillation (AF) patients at high thromboembolic risk. However, comparative effectiveness across clinical outcomes, particularly across study designs, remains incompletely characterized. Hypothesis: LAAO is non-inferior to OACs for ischemic stroke and systemic thromboembolism (STE) while conferring superior bleeding and mortality outcomes. Methods: A systematic review and meta-analysis was conducted per PRISMA guidelines. Studies comparing LAAO versus OACs in AF patients were included. Primary outcomes were all-cause mortality and major bleeding. Secondary outcomes included cardiac mortality, ischemic stroke, and STE. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were estimated via random-effects models. Heterogeneity was quantified using I 2 and tau 2 . Subgroup analyses by study design (randomized controlled trials [RCTs] versus observational) and leave-one-out sensitivity analyses were performed. Meta-regression assessed the influence of age imbalance between arms. Publication bias was evaluated via contour-enhanced funnel plots. Results: Ten studies comprising 6,094 LAAO and 5,864 OAC patients were analyzed for all-cause mortality; twelve studies (15,684 vs. 15,454) for bleeding; seven for cardiac mortality (4,466 vs. 4,373); nine for ischemic stroke (14,784 vs. 14,560); and nine for STE (13,523 vs. 13,171). LAAO was associated with a non-significant reduction in all-cause mortality (OR 0.73, 95% CI 0.52-1.03; I 2 =83.1%) and a significant reduction in major bleeding (OR 0.71, 95% CI 0.51-0.97; I 2 =86.0%) and cardiac mortality (OR 0.72, 95% CI 0.52-0.99; I 2 =73.2%). Ischemic stroke (OR 0.89, 95% CI 0.70-1.14; I 2 =48.9%) and STE (OR 0.92, 95% CI 0.53-1.60; I 2 =0%) were similar between groups. Subgroup analysis revealed observational studies influenced mortality and bleeding reductions, while RCTs showed neutral effects. Leave-one-out analyses confirmed robustness of all estimates. Meta-regression showed age imbalance did not significantly moderate any outcome (all p>0.05). Conclusions: LAAO significantly reduces major bleeding and cardiac mortality compared to OACs, with comparable ischemic stroke and STE rates. Substantial heterogeneity and design-dependent effect modification underscore the need for adequately powered RCTs to confirm mortality benefits.